News25/Ratings7
News · 26 weeks55+50%
2025-10-262026-04-19
Mix1690d
- Other8(50%)
- SEC Filings3(19%)
- Insider3(19%)
- Leadership1(6%)
- Offering1(6%)
Latest news
25 items- SECAmendment: SEC Form SCHEDULE 13D/A filed by Celularity Inc.SCHEDULE 13D/A - Celularity Inc (0001752828) (Subject)
- SECCelularity Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Material Modification to Rights of Security Holders, Leadership Update, Other Events, Financial Statements and Exhibits8-K - Celularity Inc (0001752828) (Filer)
- PRNEXGEL New Strategic Partner, Sequence LifeScience™, Leads Financing with $5.5 Million to Complete Acquisition of Celularity Degenerative Disease SegmentTransaction expected to approximately triple NEXGEL's annual revenue to approximately $35 million and is expected to be immediately accretive to profitability Licensing and acquiring a diversified suite of 6 established regenerative biomaterial products, most with existing insurance reimbursement, along with three new product 510(k) filings planned for 2026, 2027, and 2028 Forms BioNX Surgical, a division of NEXGEL LANGHORNE, Pa. , April 21, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consume
- PRCelularity Announces Closing of Transaction with NexGelFLORHAM PARK, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a longevity-focused regenerative and cellular medicine company, today announced the closing of its previously announced transaction with NexGel, Inc. ("NexGel"), pursuant to which NexGel acquired certain commercial and other assets related to Celularity's biomaterials product portfolio and received an exclusive license to develop and commercialize specified products. The transaction is intended to monetize Celularity's biomaterials portfolio while enabling it to further concentrate resources on advancing its longevity-focused therapeutic pipeline and scalable manufacturing platform. Under
- PRCelularity Announces Receipt of Nasdaq Notice Regarding Late Form 10-K FilingFLORHAM PARK, N.J., April 17, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) (the "Company"), a longevity-focused regenerative and cellular medicine company, today announced that on April 16, 2026, the Company received notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that, because it has not yet filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, the Company is not currently in compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of periodic financial reports with the Securities and Exchange Commission. The notice has no immediate effect on the listing or trading of the
- INSIDERSEC Form 4 filed by Hariri Robert J4 - Celularity Inc (0001752828) (Issuer)
- INSIDERSEC Form 4 filed by Brigido Stephen4 - Celularity Inc (0001752828) (Issuer)
- INSIDERSEC Form 4 filed by Haines John R4 - Celularity Inc (0001752828) (Issuer)
- SECSEC Form NT 10-K filed by Celularity Inc.NT 10-K - Celularity Inc (0001752828) (Filer)
- PRNEXGEL Announces Consideration Terms of Agreement to License and Acquire Portfolio of Commercial-Stage Regenerative Biomaterial ProductsConsideration for portfolio will consist of a $15 million upfront cash payment and potentially an additional $20 million in milestone payments based on net sales targets related to the portfolio Transaction expected to approximately triple NEXGEL's annual revenue to about $35 million and is expected to make the Company immediately profitable upon closing LANGHORNE, Pa., March 12, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the consideration terms of its
- PRCelularity Reiterates Strategic Commercialization Partnership with NEXGEL Focused on Building Biomaterials Franchise with Established Commercial Products and New 510(k) Pathway Product OpportunitiesBiovance, Biovance 3L, Natalin, Acelagraft, Interfyl and Centaflex licensed to NEXGEL are established commercial products widely used today in wound care, orthopedics and other indications.Three pipeline 510(k) medical device pathway programs SPARK, FUSE, and ORCHID licensed to NEXGEL are potential market disruptors.Celularity will be the exclusive manufacturer of the licensed products at its FDA-compliant facility in Florham Park, New Jersey, where its vertically integrated manufacturing infrastructure is designed to support scalable, quality-driven production for both commercial-stage products and next-generation placental-derived cellular therapeutics. FLORHAM PARK, N.J., March 12, 2026
- SECCelularity Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits8-K - Celularity Inc (0001752828) (Filer)
- PRNEXGEL Signs Definitive Agreement to License and Acquire Transformative Portfolio of Commercial-Stage Regenerative Biomaterial ProductsTransaction expected to approximately triple NEXGEL's annual revenue to about $35 million and is expected to make the Company immediately profitable upon closing Licensing and acquiring a diversified suite of 6 established regenerative biomaterial products, most with existing insurance reimbursement, along with three new product 510(k) filings planned for 2026, 2027, and 2028 Experienced commercial team is expected to join NEXGEL, significantly expanding the Company's sales reach and operational capabilities LANGHORNE, Pa., March 10, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) pr
- PRCelularity Secures $35 Million Strategic License Deal, Strengthens Capital Position to Advance Longevity-Focused StrategyTransaction expected to generate up to $35 million in upfront and milestone paymentsCelularity retains exclusive manufacturing rights, creating continued biomaterials revenue and margin opportunityOrganizational realignment reduces operating expenses and sharpens focus on longevity therapeutics FLORHAM PARK, N.J., March 10, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity" or the "Company"), a regenerative and cellular medicine company focused on longevity science, today announced that it has entered into definitive agreements establishing a strategic commercialization partnership for its placental-derived biomaterials portfolio. The transaction is expected to close n
- SECCelularity Inc. filed SEC Form 8-K: Leadership Update8-K - Celularity Inc (0001752828) (Filer)
- PRCelularity Receives $12.2 Million from Sale of New Jersey Net Operating LossesFLORHAM PARK, N.J., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a longevity-focused regenerative and cellular medicine company, today announced receipt of $12.2 Million in net cash proceeds from the sale of approximately $126.3 Million of its unused New Jersey net operating losses (NOLs) and $1.9 Million of unused New Jersey research and development (R&D) tax credits. The NOLs and R&D tax credits sale was administered through New Jersey's Technology Business Tax Certificate Transfer Program, which enables qualified New Jersey-based technology and life science companies to sell their New Jersey NOLs and R&D tax credits for cash to buyers who purchase and
- SECCelularity Inc. filed SEC Form 8-K: Leadership Update8-K - Celularity Inc (0001752828) (Filer)
- INSIDERAmendment: Director Parks Diane L. was granted 30,000 shares, increasing direct ownership by 6% to 520,021 units (SEC Form 4)4/A - Celularity Inc (0001752828) (Issuer)
- INSIDERAmendment: Director Ling Geoffrey M.D. was granted 19,231 shares, increasing direct ownership by 8% to 256,026 units (SEC Form 4)4/A - Celularity Inc (0001752828) (Issuer)
- INSIDERAmendment: Director Diamandis Peter was granted 20,385 shares, increasing direct ownership by 5% to 394,150 units (SEC Form 4)4/A - Celularity Inc (0001752828) (Issuer)
- INSIDERAmendment: Director Levien Vincent was granted 28,847 shares, increasing direct ownership by 23% to 153,847 units (SEC Form 4)4/A - Celularity Inc (0001752828) (Issuer)
- INSIDERDirector Ling Geoffrey M.D. was granted 19,231 shares, increasing direct ownership by 8% to 256,026 units (SEC Form 4)4 - Celularity Inc (0001752828) (Issuer)
- INSIDERDirector Levien Vincent was granted 28,847 shares, increasing direct ownership by 23% to 153,847 units (SEC Form 4)4 - Celularity Inc (0001752828) (Issuer)
- INSIDERDirector Diamandis Peter was granted 20,385 shares, increasing direct ownership by 5% to 394,150 units (SEC Form 4)4 - Celularity Inc (0001752828) (Issuer)
- INSIDERDirector Parks Diane L. was granted 30,000 shares, increasing direct ownership by 6% to 520,021 units (SEC Form 4)4 - Celularity Inc (0001752828) (Issuer)